Elicio Therapeutics to present Phase 2 pancreatic cancer vaccine results at SITC 2026
ELTX•Elicio Therapeutics will present Phase 2 AMPLIFY-7P results for camupepimut in KRAS-mutated pancreatic cancer at SITC in Phoenix, November 4-8, 2026. The company says the randomized trial linked vaccine-induced immune responses to improved clinical outcomes.
1. Clinical results presentations
Elicio Therapeutics will present results from its Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer at SITC in Phoenix. Clinical presentations are scheduled for November 6 and 7, and the trial linked vaccine-induced immune responses to improved clinical outcomes.
2. Preclinical presentation
A November 7 presentation will report durable antitumor activity from direct tumor delivery of amphiphilic immunomodulators.
